Plerixafor, as a CXCR4 antagonist, has significantly more efficacy in mobilizing and maintaining CD34+ cells and cells for cancer immunotherapy, chemotherapy, and radiotherapy when exacerbated with any standard cancer treatment, including chemotherapy, immunotherapy, radiotherapy, or a combination of all (Crees et al., 2023). This evidence concerns the gene CD34 and cancer.